Réactifs et instruments pour l'immunologie, la biologie cellulaire et la biologie moléculaire.
 
> A83-01 [909910-43-6]

A83-01 [909910-43-6]

Imprimer Imprimer
Identifiez-vous

Référence orb1304606-5mg

Conditionnement : 5mg

Marque : Biorbyt

Contactez votre distributeur local :


Téléphone : +1 850 650 7790

A83-01

SKU: orb1304606

Description

A 83-01 is a potent inhibitor of TGF-β type I receptors ALK5, ALK4, and ALK7. It facilitates the generation of induced pluripotent stem cells (iPSCs) from somatic cells and is widely used to support the growth and maintenance of various organoid cultures in vitro.

Research Area

Stem Cell & Developmental Biology

Images & Validation

−
A83-01

Key Properties

−
CAS Number909910-43-6
MW421.5
Purity>98%
FormulaC25H19N5S
SMILESCc1cccc(n1)-c1nn(cc1-c1ccnc2ccccc12)C(=S)Nc1ccccc1
TargetKinase
SolubilitySoluble in DMSO (up to 20 mg/ml).

Bioactivity

−
Target IC50
ALK5:12 nM|ALK4:45 nM|ALK7:7.5 nM
In Vivo
METHODS: To detect anti-tumor activity in vivo, A 83-01 (150 μg/each) was administered intraperitoneally three times a week for four weeks to a B6C3F1 mouse model of peritoneal spread of HM-1 cancer. RESULTS: Ascites formation tended to be slower in the A 83-01-treated group, and A 83-01 significantly improved the survival rate of the mice. METHODS: To investigate the role in myocardial injury, A 83-01 (10 mg/kg) was administered intraperitoneally to Nkx2.5 enh-Cre/mTmG mice once daily for seven days. RESULTS: A 83-01 treatment significantly increased the number of Nkx2.5+ myocardial myofibroblasts at baseline and after myocardial injury, leading to an increase in the number of newly formed myocardial cells. A 83-01 treatment significantly improved ventricular elasticity and stroke work, which led to an improvement of contractility after injury.
In Vitro
METHODS: Wild-type mink lung epithelial cells, Mv1Lu, were treated with A 83-01 (0.03-10 μM) and TGF-β (1 ng/mL) for 48 h, and cell proliferation was detected using a Coulter counter. RESULTS: A 83-01 prevented the inhibition of Mv1Lu cell growth by TGF-β in a dose-dependent manner. METHODS: Mouse ovarian cancer cells HM-1 were treated with A 83-01 (1-10 μM) for 30 min, followed by treatment with TGF-β (1-10 ng/mL) for 60 min, and the expression levels of target proteins were detected using Western Blot. RESULTS: The addition of TGF-β1 increased the expression of pSmad3, and A 83-01 inhibited the up-regulation of TGF-β.
Cell Research
HM-1 cells are seeded into a 96-well plate and are incubated for 18 hr. A-83-01 (1 μM) or vehicle are then added for 12 hr followed by the addition of TGF-β1 (1 ng/mL) or vehicle for 60 hr. The number of viable cells in each well is examined using the WST-1 assay following the manufacturer's instructions.

Storage & Handling

−
Storage-20°C
Expiration Date12 months from date of receipt.
DisclaimerFor research use only

Alternative Names

−
A8301, A83-01, A 83 01, A 8301, A 83-01, ALK4, ALK5, ALK5 Inhibitor IV, ALK, ALK7, inhibit, Inhibitor, TGF-β/Smad, TGFβ, TGF-β Receptor, Transforming growth factor beta receptors, TGFbeta, TGF-b/Smad, TGFb, TGF-beta, TGFbeta/Smad, Smad
−
  • AS-8351

    AS-8351 [orb1223986]

    >98% (HPLC)

    796-42-9

    291.31

    C17H13N3O2

    5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg, 500 mg, 1 g
  • A 83-01

    A 83-01 [orb1223680]

    >98% (HPLC)

    909910-43-6

    421.5168

    C25H19N5S

    5 mg, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg, 1 g
  • A83-01

    A83-01 [orb3066690]

    5 mg, 25 mg

Compound Identifiers

PubChem CID
16218924 ↗

Key Properties

−
Failed to load PubChem data

Protocol Information